Cell Gene Therapy Bioprocessing Demand For Better Process Control Expertise CMOs

Cell & Gene Therapy Bioprocessing: Demand For Better Process Control, Expertise & CMOs
By Ronald A. Rader and Eric S. Langer, BioPlan Associates, Inc.
Manufacturing capacity for both cellular therapies and gene therapy viral vectors remains in short supply.  From our research, including interviews with developers, there is a current and worsening capacity crunch. BioPlan Associates, Inc. annually surveys biopharmaceutical manufacturing professionals and publishes data on capacity and other industry concerns.
1 The survey, now in its 18
th year, includes 147 end users’ responses and also provides input from 101 suppliers/vendors worldwide. This year, we find that the industry continues to demand innovative solutions from its suppliers in key areas, but these can often be slow to develop. 

Related Keywords

China ,Ronalda Rader ,Erics Langer , ,Biopharmaceutical Manufacturing ,Bioplan Associates ,Bioplan Associates Inc ,Biopharmaceutical Technology ,Technology Transfer Directory ,Plan Associates ,Annual Survey ,Annual Report ,Needed Improvements ,Gene Therapies ,Antiviral Agents Bulletin ,Federal Bio Technology Transfer Directory ,Biopharmaceutical Products ,European Markets ,Biobetters Pipeline ,Large Scale Biopharmaceutical Manufacturing ,சீனா ,ஏரிக்ஸ் லாங்கர் ,தொழில்நுட்பம் பரிமாற்றம் அடைவு ,திட்டம் கூட்டாளிகள் ,ஆண்டு கணக்கெடுப்பு ,ஆண்டு அறிக்கை ,கீந் சிகிச்சைகள் ,கூட்டாட்சியின் உயிர் தொழில்நுட்பம் பரிமாற்றம் அடைவு ,ஐரோப்பிய சந்தைகள் ,